Combined delivery of engineered virus with immunotherapy is safe and improves outcomes in subset of patients with glioblastoma

May 18, 2023
Study validates safety of combination approach, offering possibilities to adapt treatment strategies to optimize outcomes.

Intratumoral delivery of an engineered oncolytic virus (DNX-2401) targeting glioblastoma (GBM) cells combined with subsequent immunotherapy was safe and improved survival outcomes in a subset of patients with recurrent GBM, according to results from a multi-institutional Phase I/II clinical trial co-led by researchers at The University of Texas MD Anderson Cancer Center and the University of Toronto.

The study, published in Nature Medicine, met its primary safety endpoint and demonstrated the combination was well tolerated overall with no dose-limiting toxicities. The study did not meet its primary efficacy endpoint of objective response rate, but the combination achieved a 12-month overall survival (OS) rate of 52.7%, which is greater than the prespecified efficacy threshold of 20%. Three patients remained alive at 45, 48 and 60 months after treatment.

MD Anderson release

By WindyNight on Adobe Stock
adobestock_296464233
ID 373539758 © Ruslan Batiuk | Dreamstime.com
dreamstime_xxl_373539758
By Dragon Claws on Adobe Stock
adobestock_551140731
ID 296570530 © Vetre Antanaviciute-meskauskiene | Dreamstime.com
dreamstime_xxl_296570530